Insilico Medicine published preclinical data for an AI‑designed PROTAC degrader targeting PKMYT1, demonstrating on‑target activity in cell lines and xenografts guided by generative Chemistry42 models. The work highlights AI’s ability to design bifunctional degraders for oncology targets with biomarker‑driven indication strategies. Separately, PsiThera, an ex‑Roivant spinout using AI to design oral TNF inhibitors, raised $47.5 million to advance molecules that aim to convert biologic‑class targets into pill form. PsiThera positions its platform to accelerate discovery by modeling protein motions that enable small‑molecule engagement of challenging targets. Taken together, the studies and financing signal growing confidence that generative AI can produce preclinical assets and attract capital, while also underscoring the need for rigorous translational validation as these tools push candidates toward IND‑enabling work.